Pan-cancer evaluation of tumor-infiltrating lymphocytes and programmed cell death protein ligand-1 in metastatic biopsies and matched primary tumors.
CPS
PD‐L1
SHIVA01
TPS
metastatic biopsies
primary tumors
tumor‐infiltrating lymphocytes
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
revised:
22
05
2024
received:
03
01
2024
accepted:
19
06
2024
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
29
7
2024
Statut:
aheadofprint
Résumé
Tumor immunological characterization includes evaluation of tumor-infiltrating lymphocytes (TILs) and programmed cell death protein ligand-1 (PD-L1) expression. This study investigated TIL distribution, its prognostic value, and PD-L1 expression in metastatic and matched primary tumors (PTs). Specimens from 550 pan-cancer patients of the SHIVA01 trial (NCT01771458) with available metastatic biopsy and 111 matched PTs were evaluated for TILs and PD-L1. Combined positive score (CPS), tumor proportion score (TPS), and immune cell (IC) score were determined. TILs and PD-L1 were assessed according to PT organ of origin, histological subtype, and metastatic biopsy site. We found that TIL distribution in metastases did not vary according to PT organ of origin, histological subtype, or metastatic biopsy site, with a median of 10% (range: 0-70). TILs were decreased in metastases compared to PT (20% [5-60] versus 10% [0-40], p < 0.0001). CPS varied according to histological subtype (p = 0.02) and biopsy site (p < 0.02). TPS varied according to PT organ of origin (p = 0.003), histological subtype (p = 0.0004), and metastatic biopsy site (p = 0.00004). TPS was higher in metastases than in PT (p < 0.0001). TILs in metastases did not correlate with overall survival. In conclusion, metastases harbored fewer TILs than matched PT, regardless of PT organ of origin, histological subtype, and metastatic biopsy site. PD-L1 expression increased with disease progression. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche (Investissements d'avenir) and Site de Recherche Intégré contre le Cancer (SiRIC)
ID : ANR-10-EQPX-03
Informations de copyright
© 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Références
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 2019; 19: 133–150.
Baraibar I, Melero I, Ponz‐Sarvise M, et al. Safety and tolerability of immune checkpoint inhibitors (PD‐1 and PD‐L1) in cancer. Drug Saf 2019; 42: 281–294.
Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol 2015; 33: 23–35.
Taghizadeh H, Marhold M, Tomasich E, et al. Immune checkpoint inhibitors in mCRPC – rationales, challenges and perspectives. Oncoimmunology 2019; 8: e1644109.
Edwards SC, Hoevenaar WHM, Coffelt SB. Emerging immunotherapies for metastasis. Br J Cancer 2021; 124: 37–48.
Patel SP, Kurzrock R. PD‐L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14: 847–856.
Kerr KM, Tsao M‐S, Nicholson AG, et al. Programmed death‐ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 2015; 10: 985–989.
Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death Ligand‐1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 2019; 143: 330–337.
Vennapusa B, Baker B, Kowanetz M, et al. Development of a PD‐L1 complementary diagnostic immunohistochemistry assay (SP142) for atezolizumab. Appl Immunohistochem Mol Morphol 2019; 27: 92–100.
Marletta S, Fusco N, Munari E, et al. Atlas of PD‐L1 for pathologists: indications, scores, diagnostic platforms and reporting systems. J Pers Med 2022; 12: 1073.
Huang Z, Chen L, Lv L, et al. A new AI‐assisted scoring system for PD‐L1 expression in NSCLC. Comput Methods Programs Biomed 2022; 221: 106829.
Inge LJ, Dennis E. Development and applications of computer image analysis algorithms for scoring of PD‐L1 immunohistochemistry. Immunooncol Technol. 2020; 6: 2–8.
Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD‐1/PD‐L1 checkpoint blockade: a systematic review and meta‐analysis. JAMA Oncol. 2019; 5: 1195–1204.
Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘immunoscore’ in the classification of malignant tumours. J Pathol 2014; 232: 199–209.
Donnem T, Kilvaer TK, Andersen S, et al. Strategies for clinical implementation of TNM‐Immunoscore in resected nonsmall‐cell lung cancer. Ann Oncol. 2016; 27: 225–232.
Vilain RE, Menzies AM, Wilmott JS, et al. Dynamic changes in PD‐L1 expression and immune infiltrates early during treatment predict response to PD‐1 blockade in melanoma. Clin Cancer Res. 2017; 23: 5024–5033.
Teng MWL, Ngiow SF, Ribas A, et al. Classifying cancers based on T‐cell infiltration and PD‐L1. Cancer Res 2015; 75: 2139–2145.
Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair‐deficient or microsatellite instability‐high colorectal cancer (CheckMate 142): an open‐label, multicentre, phase 2 study. Lancet Oncol 2017; 18: 1182–1191.
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD‐1 blockade. Science 2017; 357: 409–413.
Bach DH, Zhang W, Sood AK. Chromosomal instability in tumor initiation and development. Cancer Res 2019; 79: 3995–4002.
Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacol Ther 2018; 189: 45–62.
Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 2017; 2017: PO.17.00073.
Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open‐label, phase 2 KEYNOTE‐158 study. Lancet Oncol 2020; 21: 1353–1365.
Kim JY, Kim WG, Kwon CH, et al. Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact. Gastric Cancer 2019; 22: 1164–1175.
Hendry S, Salgado R, Gevaert T, et al. Assessing tumor‐infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol 2017; 24: 235–251.
Herrington CS, Poulsom R, Coates PJ. Recent advances in pathology: the 2020 annual review issue of the journal of pathology. J Pathol 2020; 250: 475–479.
García‐Corbacho J, Indacochea A, González Navarro AE, et al. Determinants of activity and efficacy of anti‐PD1/PD‐L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker‐based study. Cancer Immunol Immunother 2023; 72: 1709–1723.
Moreira A, Masliah‐Planchon J, Callens C, et al. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO scale for clinical actionability of molecular targets. Eur J Cancer. 2019; 121: 202–209.
Le Tourneau C, Delord J‐P, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open‐label, proof‐of‐concept, randomised, controlled phase 2 trial. Lancet Oncol 2015; 16: 1324–1334.
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor‐infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol 2015; 26: 259–271.
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE‐048): a randomised, open‐label, phase 3 study. Lancet 2019; 394: 1915–1928.
Gonzalez‐Ericsson PI, Stovgaard ES, Sua LF, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol 2020; 250: 667–684.
Mok TSK, Wu Y‐L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD‐L1‐expressing, locally advanced or metastatic non‐small‐cell lung cancer (KEYNOTE‐042): a randomised, open‐label, controlled, phase 3 trial. Lancet 2019; 393: 1819–1830.
Zeeshan R, Mutahir Z. Cancer metastasis ‐ tricks of the trade. Bosn J Basic Med Sci 2017; 17: 172–182.
Remark R, Alifano M, Cremer I, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013; 19: 4079–4091.
Loi S, Salgado R, Schmid P, et al. Association between biomarkers and clinical outcomes of pembrolizumab monotherapy in patients with metastatic triple‐negative breast cancer: KEYNOTE‐086 exploratory analysis. JCO Precis Oncol. 2023; 7: e2200317.
vonHardenberg J, Hartmann S, Nitschke K, et al. Programmed death ligand 1 (PD‐L1) status and tumor‐infiltrating lymphocytes in hot spots of primary and liver metastases in prostate cancer with neuroendocrine differentiation. Clin Genitourin Cancer 2019; 17: 145–153.e5.
Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA‐4 blockade relies on the gut microbiota. Science 2015; 350: 1079–1084.
Sivan A, Corrales L, Hubert N, et al. Commensal difidobacterium promotes antitumor immunity and facilitates anti–PD‐L1 efficacy. Science 2015; 350: 1084–1089.
Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple‐negative breast cancer (KEYNOTE‐355): a randomised, placebo‐controlled, double‐blind, phase 3 clinical trial. Lancet 2020; 396: 1817–1828.
Ullah A, Pulliam S, Karki NR, et al. PD‐L1 over‐expression varies in different subtypes of lung cancer: will this affect future therapies? Clin Pract 2022; 12: 653–671.
Qi Y, Zhang L, Wang Z, et al. Efficacy and safety of anti‐PD‐1/ PD‐L1 monotherapy for metastatic breast cancer: clinical evidence. Front Pharmacol 2021; 12: 653521.
Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7‐H1 expression and immunoresistance in glioma. Nat Med 2007; 13: 84–88.
Song M, Chen D, Lu B, et al. PTEN loss increases PD‐L1 protein expression and affects the correlation between PD‐L1 expression and clinical parameters in colorectal cancer. PLoS One 2013; 8: e65821.
Dong H, Strome SE, Salomao DR, et al. Tumor‐associated B7‐H1 promotes T‐cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793–800.
Li Y, Li F, Jiang F, et al. A mini‐review for cancer immunotherapy: molecular understanding of PD‐1/PD‐L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci 2016; 17: 1151.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.
Wang HB, Yao H, Li CS, et al. Rise of PD‐L1 expression during metastasis of colorectal cancer: implications for immunotherapy. J Dig Dis 2017; 18: 574–581.
Hong L, Negrao MV, Dibaj SS, et al. Programmed death‐ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC. J Thorac Oncol. 2020; 15: 1449–1459.
Engerud H, Berg HF, Myrvold M, et al. High degree of heterogeneity of PD‐L1 and PD‐1 from primary to metastatic endometrial cancer. Gynecol Oncol 2020; 157: 260–267.
Li M, Li A, Zhou S, et al. Heterogeneity of PD‐L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer 2018; 18: 4.
Salgado R, Bellizzi AM, Rimm D, et al. How current assay approval policies are leading to unintended imprecision medicine. Lancet Oncol 2020; 21: 1399–1401.